Next Catalyst
65% Interim Readout on Mino-Lok P3 Trial ~ May 2021
LINK:
https://frugalnorwegian.com/ctxr/
Don't know if true or not nor where the source for the date came from.
Recent CTXR News
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution • PR Newswire (US) • 05/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:05:34 PM
- Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution • PR Newswire (US) • 05/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:26:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:05:42 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 05/14/2024 08:05:00 PM
- Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences • PR Newswire (US) • 05/10/2024 12:30:00 PM
- Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering • PR Newswire (US) • 04/30/2024 08:05:00 PM
- Citius Pharmaceuticals Announces $15 Million Registered Direct Offering • PR Newswire (US) • 04/26/2024 12:00:00 PM
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma • PR Newswire (US) • 04/11/2024 12:30:00 PM
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference • PR Newswire (US) • 04/04/2024 12:30:00 PM
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/04/2024 05:15:18 AM
- Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:23:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2024 09:18:59 PM
- Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences • PR Newswire (US) • 02/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:45:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:40:26 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 02/14/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:18:38 PM
- Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 02/14/2024 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 09:08:28 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM